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cytoplasmic CwlM. The phosphorylated
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Tuberculosis claims >1 million lives annually, and
its causative agent Mycobacterium tuberculosis
is a highly successful pathogen. Protein kinase B
(PknB) is reported to be critical for mycobacterial
growth. Here, we demonstrate that PknB-depleted
M. tuberculosis can replicate normally and can syn-
thesize peptidoglycan in an osmoprotective medium.
ComparativephosphoproteomicsofPknB-producing
and PknB-depleted mycobacteria identify CwlM, an
essential regulator of peptidoglycan synthesis, as a
major PknB substrate. Our complementation studies
of a cwlM mutant of M. tuberculosis support CwlM
phosphorylation as a likely molecular basis for PknB
being essential formycobacterial growth.Wedemon-
strate that growing mycobacteria produce two forms
of CwlM: a non-phosphorylated membrane-associ-
ated form and a PknB-phosphorylated cytoplasmic
form. Furthermore, we show that the partner proteins
for the phosphorylated and non-phosphorylated
forms of CwlM are FhaA, a fork head-associated
domain protein, andMurJ, a proposed lipid II flippase,
respectively. Fromour results, we propose amodel in
which CwlM potentially regulates both the biosyn-
thesisofpeptidoglycanprecursorsand their transport
across the cytoplasmic membrane.INTRODUCTION
Tuberculosis remains a major global threat that claimed
1.3 million lives in 2016 (World Health Organization, 2017). More-This is an open access article undover, one-third of the entire world population is estimated to be
latently infected with Mycobacterium tuberculosis. Multiple fac-
tors contribute to the difficulty of eradicating tuberculosis; how-
ever, the remarkable ability of M. tuberculosis to persist in vivo
and to survive stressful conditions is believed to be a major
contributor to the success of this pathogen (Wayne and Sohas-
key, 2001). The ability of mycobacteria to adapt to varying
environmental constraints is governed by numerous transcrip-
tional, translational, and post-translational regulatory mecha-
nisms. In particular, protein phosphorylation controls enzyme
activity, protein-protein interactions, and protein localization.
M. tuberculosis possesses 11 serine/threonine protein kinases
(Prisic and Husson, 2014), two of which—protein kinase A
(PknA) (Nagarajan et al., 2015) and protein kinase B (PknB) (Fer-
nandez et al., 2006)—are essential for growth. PknB is one of the
most studied mycobacterial proteins and is a verified drug target
(Squeglia et al., 2017). PknB has several domains, all of which are
essential for its function (Chawla et al., 2014; Prigozhin et al.,
2016). The extracellular PASTA (penicillin-binding protein and
serine/threonine kinase associated) domain is believed to recog-
nize peptidoglycan fragments, and it has been implicated in
PknB localization (Yeats et al., 2002; Mir et al., 2011), while the
juxtamembrane domain recruits FhaA (Roumestand et al.,
2011) and possibly other proteins that control peptidoglycan
biosynthesis. PknB has been shown to phosphorylate multiple
substrates, including proteins involved in peptidoglycan biosyn-
thesis and remodeling: PonA1 (Kieser et al., 2015), GlmU (Parikh
et al., 2009), MviN (Gee et al., 2012), and CwlM (Boutte et al.,
2016). In addition, PknB interacts with Mur ligases (Munshi
et al., 2013) and proteins associated with lipid metabolism
(Wu et al., 2017). However, the reason for PknB essentiality is
currently unknown.
Here, we present multiple facts and results that demonstrate
that PknB-depleted M. tuberculosis can survive and replicate
in osmoprotective medium, suggesting that under theseCell Reports 25, 57–67, October 2, 2018 ª 2018 The Authors. 57
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Osmoprotective Medium Sup-
ports Growth of a Conditional pknB Mutant
(A–E) M. tuberculosis mutant was grown in stan-
dard 7H9 medium with (7H9+pri) or without
(7H9pri) pristinamycin or in sucrose-magnesium
medium with (SMM+pri) or without (SMM-pri) pristi-
namycin at 37C with shaking. Growth was moni-
tored by (A) measurement of optical density at
580 nm and by (B) assessment of colony-forming
unit (CFU) counts on 7H10 agar. Data are repre-
sented as means ± SEMs (n = 6).
(C) PknB was detected using anti-PknB antibody;
relative intensity of PknB bands presented as
means ± SEMs (n = 3).
(D) Scanning electron micrographs of
M. tuberculosis bacteria.
(E) Detection of nascent peptidoglycan by Van-
BODIPY labeling. Scale bars, 1 mm.conditions, PknB is not critical for bacterial growth and division.
Our findings confirm that CwlM is a major substrate of PknB and
demonstrate that phosphorylation determines both the cellular
localization and molecular interactions of CwlM in the control
of peptidoglycan biosynthesis.
RESULTS
Osmoprotective Medium Supports Growth of
PknB-Depleted M. tuberculosis
According to previously published data, PknB depletion leads to
the cessation of mycobacterial growth and to mycobacterial
lysis (Kang et al., 2005; Forti et al., 2009), thus precluding any
systematic analysis using omics technologies. To overcome
this challenge, we developed a special osmoprotective medium
and used it to investigate the growth and survival of the previ-
ously described pknB conditional mutant of M. tuberculosis,
pknB-CM (Forti et al., 2009). In our experiments, the conditional
mutant grew in standard 7H9 medium supplemented with pris-
tinamycin, the inducer of pknB expression, while the omission
of pristinamycin resulted in growth inhibition and in the accumu-
lation of lysed bacteria, consistent with the previous analysis
(Forti et al., 2009) (Figures 1A, 1B, and 1D). Osmoprotective su-
crose-magnesiummedium (SMM) not only prevented the lysis of
the mutant but also supported its growth, even without pristina-
mycin (Figures 1A and 1B). Western blot analysis using anti-58 Cell Reports 25, 57–67, October 2, 2018PknB antibody confirmed that PknB
was depleted to <5% of the original level
in media lacking pristinamycin (Fig-
ure 1C), and qRT-PCR analysis showed
that pknB expression was indeed
downregulated 8.6 ± 0.6-fold in pristi-
namycin-depleted cultures (SMMpri)
compared with pristinamycin-supple-
mented bacteria (SMM+pri). SMMpri
pknB-CM cells retained pristinamycin-
dependent growth in standard media,
so they were not escape mutants with
uncontrolled pknB expression. Further-more, SMM itself did not significantly influence the growth of
pknB-CM in the presence of pristinamycin (Figure 1). Thus, our
results demonstrated that the pknB-depleted M. tuberculosis
bacilli were able to survive and grow in SMM. Although the bac-
teria had a minor growth defect under these conditions, they still
reached stationary phase. The pknB-CM did not grow on solid-
ified SMM without pristinamycin. PknB-CM cells grown in liquid
SMM were slightly swollen but showed no significant cellular
damage in scanning electron micrographs (Figure 1D), in
contrast to pknB-CM bacteria grown in standard medium
without pristinamycin. Notably, SMMpri cells were distinct
from the L-forms described for various bacterial species (Erring-
ton et al., 2016) and had a properly formed cell envelope
(Figure 1D). To investigate peptidoglycan biosynthesis in the
pknB-CM, we performed BODIPY FL vancomycin-labeling ex-
periments. Vancomycin binds to the D-alanine-D-alanine compo-
nent of nascent peptidoglycan and is used to label the myco-
bacterial cell wall (Joyce et al., 2012; Gee et al., 2012). The
pknB-CM cells grown in SMMpri were able to bind BODIPY
FL vancomycin, indicating the production of nascent peptido-
glycan (Figure 1E).
In summary, our osmoprotective medium supports the
growth of PknB-depleted mycobacteria, thus providing a useful
tool for investigating the role of PknB in mycobacterial biology
and enabling us to conduct phosphoproteomic analyses of
PknB-producing and PknB-depleted M. tuberculosis.
Table 1. Peptides with Increased Phosphorylation in PknB-Producing M. tuberculosis
Protein Gene Function Essential Y/N Identified Phosphopeptidesa Fold Change
PknB Rv0014c serine/threonine protein kinase Y TSLLSSAAGNLSGPRTDPLPR 33.50
AIADSGNSVTQTAAVIGTAQYLSPEQAR 10.40
AIADSGNSVTQTAAVIGTAQYLSPEQAR 6.11
UvrA Rv1638 exonuclease N FLAEVVGGGASAATSR 5.21
EspI Rv3876 secretion protein EspI N RVHPDLAAQHAAAQPDSITAATTGGR 4.43
VHPDLAAQHAAAQPDSITAATTGGR 2.2
Rv2406c Rv2406c conserved protein N MGELEAEQQQLQSYITQG 3.9
CwlM Rv3915 N-acetyl-muramyl-L-alanine
amidase homolog
Y NDRPTGTFTFAELLAHELSVER 3.83
NDRPTGTFTFAELLAHELSVER 3.82
RodA Rv0017c cell division protein N SPITAAGTEVIERV 3.03
Lsr2 Rv3597 H-NS-like protein AGb IPADVIDAYHAAT 2.53
TrxB1 Rv1471 thioredoxin N AYEVEAGEATTQNGR 2.45
CysA1 Rv2397c ABC transporter AG GGTEAGNLATSMMK 2.38
EthR Rv3855 transcription repressor N TTSAASQASLPR 2.29
RpsC Rv0707 ribosomal protein Y AAGGEEAAPDAAAPVEAQSTES 2.28
FadE10 Rv0873 acyl-CoA de hydrogenase N AQQTQVTEEQAR 2.27
Rv2908c Rv2908c hypothetical protein AG SAVVVDAVEHLVR 2.03
CoA, coenzyme A. See also Table S1 and Figure S1.
aPhosphorylated residues are shown in bold font.
bAG, advantageous for growth.PknB Depletion Leads to Global Changes in Protein
Phosphorylation
A comparative analysis of phosphoproteins from PknB-depleted
(SMMpri) and PknB-producing (SMM+pri) M. tuberculosis cul-
tures revealed global changes in phosphorylation patterns
(Table S1). The depletion of PknB resulted in the increased phos-
phorylation of various proteins, including serine/threonine protein
kinase PknA. Other abundant phosphoproteins in the SMMpri
cultures were ribosomal proteins, heat shock proteins, trans-
porters,and factors involved incell division.Severalpreviouslyan-
notatedPknBsubstrates such asMurJ (also knownasMviN) (Gee
et al., 2012), FhaA (Roumestand et al., 2011), and GarA (Villarino
et al., 2005) that control peptidoglycan biosynthesis and central
metabolism showed increased phosphorylation in the PknB-
depleted samples (Table S1). In addition, phosphorylated MtrA
and PrrA, two component response regulators essential for
M. tuberculosis growth (Zahrt and Deretic, 2000; Haydel et al.,
2012), were more abundant in the PknB-depleted cultures.
To identify potential PknB-specific substrates, we analyzed
phosphopeptides that were enriched in SMM+pri cultures
relative to SMMpri cultures. In total, 13 proteins were found to
be >2-fold more phosphorylated in SMM+pri samples; 6 of
them had been previously annotated as proteins essential or
advantageous for M. tuberculosis growth (DeJesus et al., 2017)
(Tables 1 and S1). As expected, PknB was the most phosphory-
lated protein in PknB-producing M. tuberculosis. Other sub-
strates with increased phosphorylation included CwlM, a pepti-
doglycan amidase homolog (Boutte et al., 2016); the annotated
enzymes, UvrA, an exonuclease (Rossi et al., 2011), and
FadE10, an acyl-dehydrogenase; transcriptional regulators
Lsr2 (Bartek et al., 2014) and EthR (Leiba et al., 2014); an RNA-binding protein, RpsC, which is involved in translation initiation;
secretion and membrane proteins EspI (Zhang et al., 2014) and
Rv2397c ABC transporter; and conserved proteins of unknown
function, Rv2406c andRv2908.Most proteins had one phospho-
site; however, PknB itself, CwlM, and EspI were phosphorylated
on several amino acids.
Among the PknB substrates showing increased phosphoryla-
tion, PknB, CwlM, and RpsC represented potential PknB sub-
strates essential for growth. In particular, CwlM, encoded by
rv3915, was the most highly phosphorylated essential protein
(after PknB itself) in the PknB-producing M. tuberculosis
compared with the PknB-depleted mycobacteria. We therefore
focused our investigation on this target. Four phosphosites were
detected in CwlM (threonine 42 [T42], T43, T382, and T386); how-
ever, only two of these (T382 and T386) were more phosphory-
lated in the PknB-producing mycobacteria (Table 1; Figure S1).
PknB was able to phosphorylateM. tuberculosis CwlM in vitro
(Figure S1). Mass spectrometry analysis of in vitro phosphory-
lated CwlM confirmed phosphorylation of T43, T382, and
T386, and identified two additional phosphorylated residues,
T94 and T384. Similarly, Boutte et al. (2016) have recently
reported that PknB phosphorylates M. tuberculosis CwlM
in vitro. The biological importance of CwlM phosphorylation at
these sites was further investigated in complementation studies.
A Phosphoablative CwlM Mutant ofM. tuberculosis
Mimics the Phenotype of PknB-Depleted Mycobacteria
We reasoned that if CwlM is the main substrate of PknB, a phos-
phoablative mutant of CwlM should reproduce the major features
of the PknB-depleted mycobacteria. We first generated a cwlM
conditional mutant of M. tuberculosis (cwlM-CM) using theCell Reports 25, 57–67, October 2, 2018 59
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Figure 2. T382A Mutant Mimics Phenotype
of PknB-Depleted M. tuberculosis
(A–D) The cwlM conditional mutant of
M. tuberculosis was transformed with pMV306
plasmids containing cwlM variants. The resultant
strains were grown in 7H9 medium (A) or in SMM
(B) without pristinamycin. All of the strains grew
similarly when 7H9 or SMM were supplemented
with pristinamycin (data not shown for clarity).
pMV, cwlM-CMpmv306 (the empty plasmid
control); CwlM, cwlM-CMWT; T382A and T382D
phosphoablative and phosphomimetic mutants,
respectively. Data are represented as means ±
SEMs (n = 6).
(C) Growth of strains on 7H10 agar.
(D) Western blot of CwlM variants detected with
anti-CwlM antibody.
See also Figures S2 and S3 and Table S3.pristinamycin-inducible system. As expected, the mutant did not
grow without pristinamycin in liquid (Figures S2A and S2B) or on
solid (FigureS2C)media.Westernblot analysisusingaCwlM-spe-
cific antibody confirmed the near-complete depletion of CwlM in
the cwlM-CM mutant upon the withdrawal of pristinamycin (Fig-
ure S2D). CwlM depletion resulted in severe cell aggregation,
the accumulation of lysed mycobacteria (Figure S2D), and the
cessation of BODIPY FL vancomycin incorporation (Figure S2F).
This dramatic phenotype could be fully complemented by
the reintroduction of cwlM with a putative upstream promoter
in an integrating plasmid, pMV306. The complemented mutant
(cwlM-CMWT) was able to grow in liquid and solid media without
pristinamycin, while a strain with an empty pMV306 plasmid
(cwlM-CMpmv306) displayed the CwlM depletion phenotype (Fig-
ure 2). A panel of site-directedmutants was generated (Table S2)
to study the importance of phosphorylation at the different thre-
onine sites. The growth patterns of the resultantM. tuberculosis
strains are summarized in Table S3. Single replacements of T42,
T43, T94, T384, or T386 (Figure S3A) with an alanine did not have
a significant effect on M. tuberculosis growth. However, myco-
bacteria expressing the T382A variant could not grow without
pristinamycin either in liquid medium (Figure 2A) or on agar (Fig-
ure 2C), highlighting the T382A mutation as being critical for
growth. The replacement of T382 with an aspartate residue
(T382D) to mimic phosphorylation resulted in a milder growth
defect (Figures 2A and 2C), while replacement of any other
phosphosites with an aspartate had no marked effect on
M. tuberculosis growth (Table S3; Figure S3).
A double phosphoablative mutation (T382A and T386A) was
very toxic to M. tuberculosis, and no transformants could be
recovered with this construct. The corresponding double phos-
phomimeticmutation (T382D+T386D)wasnot toxic formycobac-60 Cell Reports 25, 57–67, October 2, 2018teria, but it did not complement themutant
phenotype (Figure S3B). These findings
suggest that phosphorylation of both thre-
onines is important for M. tuberculosis
growth.
We next investigated whether the
phosphoablative T382A version ofcwlM-CM could grow in osmoprotective medium. CwlM-CM
and cwlM-CMpmv306 strains did not grow in SMM (Figure 2B),
while the cwlM-CMWT and the T382Dphosphomimetic grew simi-
larly in standard and SMM (Figures 2A and 2B). Furthermore, the
T382A variant was able to grow in SMMpri (Figure 2B) and to
incorporate BODIPY FL vancomycin (data not shown), thus
mimicking the phenotype of the PknB-depleted M. tuberculosis.
As demonstrated in Figure 2D, all of the variant proteins were pro-
duced at similar levels. Attempts to complement the pknB-CM
mutantwith any of the phosphomimetic formswere unsuccessful.
CwlM Is Present in Two Distinct Forms during
Mycobacterial Growth
The phenotypes of PknB-depleted and CwlM-depleted myco-
bacteria, as well as those of the phosphoablative and phospho-
mimetic CwlMM. tuberculosismutants in the present study, sug-
gest that both phosphorylated and non-phosphorylated forms of
CwlM play important roles in mycobacterial growth. We hypoth-
esized that the phosphorylated and non-phosphorylated forms
may have different cellular localizations. To test our hypothesis,
we performed cell fractionation for western blot analysis and
investigated the presence of CwlM in cwlM-CM and pknB-CM
samples. As shown in Figure 3, CwlM was detected in both the
cytoplasmic and membrane fractions of cwlM-CMWT (Figure 3A,
wild-type [WT]) and of pristinamycin-induced pknB-CM (Fig-
ure 3B, 7H9+pri and SMM+pri). Similar results were obtained in
WT M. tuberculosis and M. smegmatis (Figure S4). Both forms
were missing in the control cwlM-CMpmv306 grown without pris-
tinamycin (Figure 3A). The T382A form was present in the mem-
brane fraction but not in the cytoplasmic fraction, while the
T382D phosphomimetic was present in both fractions, with a
slight reduction in the membrane fraction. Furthermore, PknB
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Figure 3. PknB-Mediated Phosphorylation
of T382 Determines Distribution of CwlM
in Cytoplasmic and Membrane Fractions of
M. tuberculosis
(A–D) Lysates obtained from cwlM-CM grown in SMM
without pristinamycin to prevent induction of genomic
cwlM (A and C) or from pknB-CM grown in SMM or
standard 7H9 medium with or without pristinamycin (B
and D) were fractionated and probed with anti-CwlM
antibodies (A and B) or with anti-T382-P and anti-T382
antibodies (C and D). Anti-GarA and Anti-GlnA anti-
bodies were used to confirm the purity of mycobac-
terial fractions.
See also Figure S4.depletion resulted in the loss of cytoplasmic but not of mem-
brane CwlM (Figure 3B). Both forms of CwlM were detectable
only during the exponential growth phase (Figure S4).
Our complementation data suggested that the phosphoryla-
tion of T382 by PknB is critical forM. tuberculosis growth in stan-
dard media. To detect the phosphorylation state of CwlM in
M. tuberculosis fractions, we generated phosphosite-specific
antibodies. Twodifferent antibodieswereused. Thefirst antibody
was raised against a peptide containing the phosphorylated form
of T382, designated as anti-T382-P antibody, and the second
was raised against an equivalent non-phosphorylated peptide,
designated as anti-T382 antibody. Western blot analysis using
anti-T382-PandM. tuberculosis lysates indicated that phosphor-
ylated CwlM was present only in the cytoplasm of cwlM-CMWT
(Figure 3C). The T382A and T382Dmutants were not phosphory-
lated, while cwlM-CMpmv306 did not produce CwlM. Consistent
with these findings, non-phosphorylatedCwlMwas not detected
in the cytoplasm, but insteadWT T382, T382A, and T382D forms
were present in the membrane fractions (Figure 3C). Further-
more, the T382 phosphorylated CwlM was mainly detected in
the cytoplasm of pristinamycin-induced pknB-CM, but it was
significantly reduced inPknB-depletedmycobacteria (Figure3D).
Non-phosphorylated CwlM was detected in the membrane frac-
tions of pknB-CM under all of the conditions tested (Figure 3D).
These results suggest that in growing bacteria, CwlM is present
as both phosphorylated and non-phosphorylated forms. The
cytoplasmic form is phosphorylated, whereas the membrane-
associated form is non-phosphorylated. In addition, PknB con-
trols the distribution of CwlM via the phosphorylation of T382.
Phosphorylated and Non-phosphorylated CwlM Have
Different Protein Partners
It has recently been reported that T382-phosphorylated CwlM
interacts with MurA, which is located in the cytoplasm and is
the first enzyme in the biosynthesis of peptidoglycan precursors,
and stimulates its activity (Boutte et al., 2016). Given that CwlM
has no predicted transmembrane domains or lipid anchors, it
was reasonable to hypothesize that the membrane-associatednon-phosphorylated form may interact with
othermembrane protein(s). To test this possi-
bility, we prepared membrane and cyto-
plasmic M. tuberculosis fractions for immu-
noprecipitation assays using the anti-CwlMantibody. Several potential partners of CwlM were identified
in cytoplasmic and membrane fractions (Table S4). These part-
ners included FhaA, FtsZ, DnaA, Wag31, and the previously
described MurA in the cytoplasmic fraction, and MurJ (MviN),
FtsE, and CwsA in the membrane fraction.
Mycobacterial protein fragment complementation assays
further confirmed that CwlM interacts with FhaA, MurJ, and
CwsA (Figure S5).MurJ is an integral membrane proteinwith pro-
posed lipid II flippase activity based on cellular assays (Sham
et al., 2014). Although the purified protein is reported to lack
lipid II transport activity (Mohammadi et al., 2011), lipid II binding
toMurJ has been detected by nativemass spectrometry and fac-
tors that influence the interaction of MurJ with lipid II identified
(Bolla et al., 2018). Mycobacterial MurJ is characterized by
unique structural properties; in addition to 14 highly conserved
transmembrane helices, it has an intracellular domain of 334
amino acids, designated asMurJicd (Gee et al., 2012).Weconsid-
ered MurJicd as the likely CwlM-binding domain and focused our
investigation on this domain rather than on the entire protein.
FhaA contains a C-terminal fork head-associated (FHA)
domain that interacts with phosphorylated proteins (Roume-
stand et al., 2011). MurJicd and FhaA have been previously
shown to interact with each other (Gee et al., 2012), and we
were intrigued by the possibility that CwlM may interact with
both proteins. We therefore generated recombinant FhaA and
MurJicd and investigated their interaction with both forms of
CwlM. Recombinant Wag31 was used as a control. As Figure 4
shows, Wag 31 did not co-precipitate with either CwlM forms,
while MurJicd mainly co-precipitated with non-phosphorylated
CwlM. Densitometric analysis of gels from three independent ex-
periments confirmed that 85% ± 6% of MurJicd was co-precipi-
tated with non-phosphorylated CwlM compared with 12% ± 6%
bound to phosphorylated CwlM. FhaA showed the opposite
binding pattern, with 84% ± 4% co-precipitating with phosphor-
ylated CwlM and only 19.7% ± 9% with non-phosphorylated
CwlM. As shown in Figure 4D, the CwlM bound to FhaA was
phosphorylated on T382, while the CwlM co-immunoprecipi-
tated with MurJicd was not phosphorylated.Cell Reports 25, 57–67, October 2, 2018 61
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Figure 4. PknB Phosphorylation Controls
the Interaction of CwlM with MurJICD and
FhaA
(A–D) PknB-phosphorylated and non-phosphory-
lated recombinant CwlM was mixed with recom-
binant FhaA (A), MurJICD (B), or Wag31 (C) and
incubated with gentle mixing for 30 min. Anti-
CwlM immunoglobulin G (IgG) Sepharose (IgG-
Seph) was then added and further incubated for
30 min. Proteins bound to Sepharose and un-
bound material were resolved on SDS-PAGE and
stained with Coomassie brilliant blue.
(D) Confirmation of CwlM phosphorylation. M,
protein markers; +, reagent added; , flow-
through fractions.
See also Figures S5 and S7 and Table S4.CwlMBinding to FhaA IsDriven byT382Phosphorylation
and Increased by T386 Phosphorylation
Our phosphoproteomics and complementation studies high-
lighted the importance of T382 and T386 phosphorylation for
M. tuberculosis growth. We therefore explored the role of these
phosphosites for binding to FhaA, using the recombinant
C-terminal domain of FhaA (designated as FHA) and synthetic
peptides corresponding to the C-terminal tail of CwlM. These
included single phospho-T382 and phospho-T386 peptides, a
double phospho-T382 and phospho-T386-peptide, a non-
phosphorylated peptide, a double phosphomimetic (T382D and
T386D), and double phosphoablative peptides (T382A and
T386A). Using two-dimensional nuclear magnetic resonance
spectroscopy, we detected chemical shifts in the [1H,15N] heter-
onuclear single quantum coherence (HSQC) spectra of the
15N-labeled FHA domain upon the addition of all of the phos-
phopeptides, indicating binding (Figure 5). Differences were
observed in the pattern of chemical shift changes in FHA for the
two single phosphopeptides. For example, the chemical shifts
of T470 and G471 were appreciably more perturbed upon the62 Cell Reports 25, 57–67, October 2, 2018addition of the T382 phosphopeptide
than upon addition of the T386 phospho-
peptide, despite the presence of two phe-
nylalanines in positions 385 and 387. This
observation indicates that the T386 phos-
phopeptidemaybindmoreweakly to FHA
compared to the binding of the T382 pep-
tide. Perturbations in the [1H,15N] HSQC
spectra of the15N labeled FHA domain,
observed upon the addition of the double
phosphopeptide, corresponded to those
observed for the single T382 phospho-
peptide (Figure S6) but with larger
changes in the chemical shifts. T470 and
T471 of FHAwere again perturbed. These
findings suggest that the primary binding
site in FHA was occupied by phospho-
T382 and that T386 phosphorylation
played an accessory role by increasing
this interaction but without replacing the
phospho-T382 as the main anchor forFHA binding. The additional phosphorylation of other FHA do-
mains has been reported to have a similar effect on protein-pro-
tein interactions (Lee et al., 2008). In control experiments, we
tested non-phosphorylated and double phosphoablative pep-
tides and did not observe any chemical shift in the FHA spectra,
while the double phosphomimetic peptide displayed a weaker
binding. The role of T384 phosphorylation in FHAandCwlM inter-
action was not investigated.
Thus, we can postulate that phosphorylation at the T382 posi-
tion is critical for the interaction of CwlMwith FhaA and that addi-
tional phosphorylation potentiates the binding of these two pro-
teins. These data further support our mutant complementation
results (Figure S3; Table S3), which together indicate that phos-
phorylated threonines have distinct roles in CwlM function.
Non-phosphorylated CwlM Interacts with an Essential
Part of MurJicd
We hypothesized that the interaction of CwlM with MurJ could
be essential for mycobacterial growth. According to Gee et al.
(2012), not all MurJ domains are essential for M. tuberculosis
Figure 5. Amide Averaged Chemical Shift
Variations (Dd) as a Function of Protein
Sequence
(A–D) Dd values were calculated between 1H-15N
HSQC spectra recorded at 800 MHz (20C and
pH 6.8) on 80 mM 15N-uniformly labeled samples of
Rv0020c-FHA before and after addition of 80 mM
concentrations of unlabeled peptides pT382–T386
(A), T382–pT386 (B), pT382–pT386 (C), or D382–
D386 (D), with Dd = [(DdH)
2 + (DdN 3 (gN/gH))
2]0.5.
The dotted lines show the SD (0.078 ppm) from the
‘‘C’’ position.
See also Figure S6.viability. Theseauthors obtained viable deletionmutantswhen the
protein was truncated at phenylalanine 715; however, shorter
truncated MurJ forms did not support mycobacterial growth.
These results indicated that the E541–F680 region of MurJicd,
which links the 14th transmembrane helix with the pseudokinase
domain, may be indispensable for mycobacterial growth, while
the non-essential pseudokinase domain (D681–R963) may have
a regulatory role via the recruitment of the FHA domain of FhaA
(Gee et al., 2012). No function has been described for the E541–
F680 region. We therefore tested whether this region can bind to
CwlM. We generated a recombinant version of this linker for use
in immunoprecipitation experiments. As shown in Figure S7, the
linker did indeed bind CwlM. Our attempts to generate a myco-
bacterial mutant lacking this region were unsuccessful, confirm-
ing previously published results on the essentiality of this part of
MurJicd (Gee et al., 2012). Thus, we established that non-phos-
phorylated CwlM interacts with an essential region of MurJ. The
lack of BODIPY FL vancomycin labeling in the CwlM-depleted
mycobacteria (Figure S2) indicates that this interaction may be
important for the production of nascent peptidoglycan.
DISCUSSION
PknB Is Not Critical for M. tuberculosis Growth in
Osmoprotective Medium
PknB-like kinases are widely distributed in Gram-positive bacte-
ria (Pereira et al., 2011). Most are not essential for bacterialCviability and they fulfill distinct biological
functions. For example, in Bacillus
subtilis, PrkC is not required for growth
and regulates spore germination (Shah
et al., 2008), while in Streptococcus pneu-
moniae, StkP is important for cell division
and cell wall remodeling (Beilharz et al.,
2012; Zucchini et al., 2018). It is widely
accepted that PknB is essential for myco-
bacterial viability (Fernandez et al., 2006)
because of its involvement in regulating
peptidoglycan biosynthesis and cell
shape (Kang et al., 2005). PknB is pro-
duced during exponential growth and its
altered expression dramatically affects
mycobacterial growth and morphology.
PknB depletion leads to the accumulationof elongated cells and to gradual bacterial lysis (Forti et al., 2009),
while pknB overexpression affects cell viability and morphology
(Kang et al., 2005). These effects of dysregulated PknB expres-
sion on bacterial viability have precluded a detailed molecular
analysis of its essentiality for mycobacterial viability, given that
altered phosphoproteomics profiles could be attributed to
‘‘dying cells.’’
In this study, we developed a special medium that prevented
the death of PknB-depleted mycobacteria and supported their
propagation. The PknB-depleted M. tuberculosis bacilli were
able to synthesize peptidoglycan and showed only marginal
changes in morphology. The need for an osmoprotective me-
dium suggests that the PknB-depleted mutant has defects in
peptidoglycan structure and that PknB has a regulatory role in
peptidoglycan biosynthesis. We have previously shown that
the overexpression of the PknB_PASTA domain partially mimics
the phenotypes of pknB-depleted mycobacteria by inhibiting
mycobacterial growth and causing increased sensitivity to mer-
openem (Turapov et al., 2015), the inhibitor of transpeptidases
and D,D-carboxypeptidase in mycobacteria (Kumar et al.,
2012). The inhibition of PknB-like kinases in other bacteria also
increases bacterial susceptibility to b-lactam antibiotics (Vorn-
hagen et al., 2015; Pensinger et al., 2018), indicating that these
kinases may control peptidoglycan biosynthesis. We therefore
propose that PknB depletion could result in defective peptido-
glycan synthesis, which is incompatible with growth in standard
conditions.ell Reports 25, 57–67, October 2, 2018 63
Figure 6. Proposed CwlM-Mediated Regu-
lation of Peptidoglycan Synthesis in Myco-
bacteria
(A) In this model, non-phosphorylated CwlM in-
teracts with the essential MurJ linker region and
activates or facilitates the transport of peptido-
glycan precursors. This activity may lead to the
accumulation of excessive amounts of peptido-
glycan, which is not incorporated into the cell wall.
(B) The PASTA domain of PknB senses un-
crosslinked peptidoglycan, resulting in the auto-
phosphorylation and activation of PknB. PknB then
phosphorylates CwlM and MurJ, which both
interact with FhaA. Phosphorylated CwlM also in-
teracts with MurA (not included for clarity). FhaA
may serve as a regulatory hub to ensure that a
balance is maintained between the phosphory-
lated and non-phosphorylated forms of CwlM and
that interactions between CwlM and its partners,
MurJ and MurA, are regulated. The red P shows
phosphorylation of PknB, CwlM, and MurJ.CwlM Is a Major PknB Substrate
A substantial number of PknB substrates have been identified
using in vitro phosphorylation assays (Prisic and Husson,
2014). Several phosphoproteomics studies have also demon-
strated a high abundance of phosphoproteins in mycobacteria
(e.g., Prisic et al., 2010); however, there is limited information
about the specific kinases that are responsible for the phosphor-
ylation of these proteins. One study attempted to identify PknB
substrates in a strain overexpressing PknB at early stationary
phase (Kang et al., 2005), while a more recent investigation
analyzed phosphopeptides from M. tuberculosis treated with
kinase inhibitors compared to untreated controls (Carette
et al., 2018).
Here, we conducted a comparative phosphoproteomics anal-
ysis of PknB-producing and PknB-depleted mycobacteria in the
exponential growth phase and identified potential PknB sub-
strates. This analysis identified CwlM as being the strongest
candidate for a main PknB substrate. CwlM is essential for
growth and is likely to be involved in the regulation of cell wall
biosynthesis. A recent study (Boutte et al., 2016) reported that
PknB phosphorylates CwlM in vitro and that a T374 phosphoa-
blative CwlM mutant of M. smegmatis had a severe growth
defect in liquid and solid media. These authors’ genetic and
biochemical evidence suggests that phosphorylated CwlM stim-
ulates the activity of MurA, the first enzyme in the biosynthesis of
peptidoglycan precursors, and that it is therefore likely to be
directly involved in the regulation of peptidoglycan precursor
production. Our findings confirm that this regulation is not essen-
tial under osmoprotective conditions.
Our study also demonstrated that the phosphorylation of T382
in CwlM is critical forM. tuberculosis growth in standard but not
in osmoprotective media. This remarkable similarity between the
phenotypes of PknB-depleted and phosphoablative-CwlM
mycobacteria, together with the direct demonstration of dramat-
ically decreased levels of phosphorylated CwlM in the PknB-
depleted strain, suggests that CwlM phosphorylation may
explain why PknB is essential for M. tuberculosis viability. How-64 Cell Reports 25, 57–67, October 2, 2018ever, the phosphorylation of other PknB substrates may also be
critical for M. tuberculosis viability under certain conditions.
Phosphorylated and Non-phosphorylated CwlM
Proteins Have Distinct Cell Localizations and Different
Protein Partners
Our results indicate that both phosphorylated and non-phos-
phorylated forms of CwlM have distinct roles in M. tuberculosis
growth. CwlM-depletedmycobacteria cannot neither grow in os-
moprotective SMM nor incorporate BODIPY FL vancomycin,
while the phosphoablative mutant can grow in SMM and incor-
porate BODIPY FL vancomycin. We were puzzled by the poten-
tial roles of the two CwlM forms and investigated whether phos-
phorylation regulates the distribution of CwlM. We established
that the phosphorylated CwlM form was mainly present in the
cytoplasm of PknB-producing mycobacteria and was minimally
detectable in the PknB-depletedM. tuberculosis. In contrast, the
non-phosphorylated form was associated with the membrane;
the T382A phosphoablative form of CwlM was found exclusively
in the membrane and the phosphomimetic form was present
predominantly in the cytoplasm of cwlM-CM. Our data suggest
that the substitution of T382 with a negatively charged amino
acid (T382D) does not fully mimic phosphorylated CwlM.
Instead, CwlM T382D possessed properties of both the phos-
phorylated and non-phosphorylated forms, which explains how
this CwlM form could complement the cwlM-CM but not the
pknB-CM of M. tuberculosis. These results imply that a balance
needs to be maintained between the phosphorylated and non-
phosphorylated forms of CwlM and that this fine balance is
essential for bacterial viability and can be affected by altered
PknB expression or activity.
CwlM is predicted to be an N-acetylmuramoyl-L-alanine
amidase; however, its actual activity remains uncertain. While
Deng et al. (2005) have previously demonstrated CwlM to
possess peptidoglycan hydrolyzing activity, in a more recent
study, no such activity was detected, presumably due to the
lack of two essential catalytic residues (Boutte et al., 2016). As
mentioned above, Boutte et al. (2016) have proposed that
phospho-CwlM controls peptidoglycan generation by activating
MurA; however, the possible functions of non-phosphorylated
CwlM were not addressed. Previously published kinetic param-
eters do not support the activation of MurA by non-phosphory-
lated CwlM (Boutte et al., 2016). Moreover, cwlM could not be
deleted in anM. smegmatis strain with anmurA S368P mutation
that rescued the growth defect of a phosphoablative cwlM
mutant (Boutte et al., 2016).
In this study, we show that non-phosphorylated CwlM inter-
acts with the essential linker region (E541–F680) of the proposed
lipid II flippase, MurJ. Furthermore, phosphorylated CwlM does
not interact with MurJ but instead binds to FhaA. CwlM-depleted
mycobacteria did not incorporate BODIPY FL vancomycin and
had a severe shape defect that can be attributed to impaired
peptidoglycan biosynthesis (Figure S2). In mycobacteria, MurJ
has an additional intracellular region that includes a pseudoki-
nase domain (KHD) (Gee et al., 2012). KHD is phosphorylated
by PknB to produce a complex with FhaA, but the precise role
of this complex is not fully understood. Previously published
data showed that the depletion of FhaA increased the incorpora-
tion of labeled vancomycin into peptidoglycan and that PknB
overexpression had an opposite effect, increasing the accumu-
lation of diaminopimelate (DAP)-containing precursors in the
cytoplasm (Gee et al., 2012). It has been therefore proposed
that PknB phosphorylation downregulates MurJ flippase activity
(Gee et al., 2012). This potential regulatory mechanism is, how-
ever, non-essential for bacterial growth because FhaA and
the pseudokinase domain of MurJ (D681–E955) could be inacti-
vated without having any impact on mycobacterial viability (Gee
et al., 2012).
We hypothesize that the binding of non-phosphorylated CwlM
to the essential MurJ linker region is necessary for the function
of MurJ, perhaps by facilitating the transport of lipid II across
themembrane and activating peptidoglycan polymerization (Fig-
ure 6A). The nascent peptidoglycan is polymerized and incorpo-
rated into the existing cell wall during growth and cell division
(Typas et al., 2011). This incorporation may be delayed under
certain conditions, for example, when cell growth slows or
when an efficient peptidoglycan synthesis complex causes
peptidoglycan material to accumulate near the cell membrane,
potentially interfering with other cell envelope processes. It
was previously proposed that the PASTA domain of PknB
senses uncrosslinked peptidoglycan (Yeats et al., 2002). The
PASTA domain may thus bind such excessive peptidoglycan
material (Figure 6B), resulting in the autophosphorylation and
activation of PknB (Barthe et al., 2010), followed by the phos-
phorylation of CwlM and MurJ. In this scenario, the phosphory-
lated CwlM dissociates from MurJ and interacts with FhaA.
Thus, PknB-mediated phosphorylation may control MurJ activity
by two independent mechanisms: (1) by phosphorylating CwlM
and preventing its interaction with MurJ and (2) by phosphory-
lating MurJ and inhibiting its activity. FhaA may serve as a regu-
latory hub to ensure that a balance is maintained between phos-
phorylated and non-phosphorylated CwlM and to regulate the
interactions between CwlM and its partners, MurJ and MurA.
This PknB-mediated regulation perhaps supports the unique
asymmetrical polar growth and peptidoglycan biosynthesis inmycobacteria (Joyce et al., 2012). Mycobacteria lack many
important components to maintain cell shape, such as MreB
(Hett and Rubin, 2008), and require properly matured peptido-
glycan to preserve their rod-like shape and cell wall integrity
(Baranowski et al., 2018).
Although the precise function and importance of the CwlM-
MurJ interaction remain to be established, our data suggest
that a distinct mechanism exists for the regulation of peptido-
glycan synthesis in mycobacteria. The activation of MurJ by
CwlM poses a significant technical challenge to demonstrate
directly, because the possible flippase activity of MurJ has not
been detected in vitro. CwlM may also be involved in the regula-
tion of other cellular processes (e.g., via its interaction with
CwsA) or it may possess other enzymatic activity. Future studies
will thus help to establish the exact molecular mechanisms that
underlie the essential role of CwlM in mycobacteria.
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Antibodies
Phospho-Threonine Antibody (P-Thr Polyclonal) Cell Signaling Technology Cat#9381, RRID:AB_330301
Monoclonal Anti-polyHistidine antibody produced in mouse Sigma-Alrdich Cat#H1029, RRID:AB_260015
Monoclonal Anti-M. tuberculosis GlnA (Gene Rv2220),
Clone IT-58
BEI Resources NR-13656
Monoclonal Anti-M. tuberculosis GroEL2 (Gene Rv0440),
Clone IT-70
BEI Resources NR-13657
Anti-PknB antibody raised in rabbit Forti et al., 2009 N/A
Custom anti-GarA antibody raised in rabbit Cambridge Biosciences
provided by H O’Hare
N/A
Custom polyclonal anti-CwlM antibody raised in rabbit Thermo Fisher Scientific N/A
Custom polyclonal antibodies raised against
GKNDRPT-phosphoGT in rabbit (anti-T382-P)
Gemini Biosciences Ltd N/A
Custom polyclonal antibody raised against
GKNDRPTGT in rabbit (anti-T382)
Gemini Biosciences Ltd N/A
Anti-Mouse IgG (whole molecule) Alkaline Phosphatase
antibody produced in rabbit
Sigma-Aldrich Cat# A3562; RRID:AB_258091
Mouse Anti-Rabbit IgG Antibody: AP Aviva Systems Biology
via Generon
Cat# OASB00822
Anti-rabbit IgG, HRP-linked Antibody Cell Signaling Technology Cat#7074; RRID:AB_2099233
Bacterial and Virus Strains
Mycobacterium tuberculosis H37Rv Laboratory stock ATCC 27294
Mycobacterium smegmatis mc2155 Laboratory stock ATCC 700084
Mycobacterium tuberculosis H37Rv conditional PknB mutant Forti et al., 2009 N/A
Mycobacterium tuberculosis H37Rv conditional CwlM mutant This study N/A
Mycobacterium tuberculosis H37Rv conditional CwlM
complemented mutants (detailed in Table S2)
This study N/A
Mycobacterium smegmatis mc2155 M-PFC strains
(detailed in Table S2)
This study N/A
Escherichia coli a-Select Gold Competent Cells BIOLINE BIO-85027
Escherichia coli OverExpress C41 (DE3) Chemically
Competent Cells
Lucigen Cat#60442-1
Escherichia coli OverExpress C41 (DE3) strains for
overexpression of recombinant proteins (detailed in Table S2)
This study N/A
Chemicals, Peptides, and Recombinant Proteins
BD Difco Dehydrated Culture Media: Middlebrook 7H9 Broth Fisher Scientific Cat#DF0713-17-9
BD Difco Dehydrated Culture Media: Middlebrook 7H10 Agar Fisher Scientific Cat#DF0627-17-4
Hygromycin B (50 mg/ml) ThermoFisher Scientific Cat#10687010
Pristinamycin Molcan Cat# PSM01A-100
cOmplete Ultra Tablets Protease Inhibitor Cocktail Sigma-Aldrich 05892970001 ROCHE
PhosSTOP phosphatase inhibitor tablets Sigma-Aldrich PHOSSRO ROCHE
Ni-NTA agarose QIAGEN Cat#30210
Glutathione Sepharose 4B GST-tagged protein purification resin GE Healthcare Life Sciences Cat#17075601
HiLoad 16/600 Superdex 200 pg prepacked column GE Healthcare Life Sciences Cat#28989335
Cyanogen bromide-activated-Sepharose 4B Sigma-Aldrich Cat#C9210
AC-NDRPTGTFTFAELLA-NH2 peptide Generon Custom synthesized
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AC-NDRPT(phospo)GTFT(phospo)FAELLA-NH2 Generon Custom synthesized
AC-NDRPT(phospho)GTFTFAELLA-NH2 Generon Custom synthesized
AC-NDRPTGTFT(phospho)FAELLA-NH2 Generon Custom synthesized
AC-NDRPAGTFAFAELLA-NH2 Generon Custom synthesized
AC-NDRPDGTFDFAELLA-NH2 Generon Custom synthesized
SERVA Gel TG Prime 4-20% 10 samples wells Generon Cat# 43277.01
SERVA Gel TG Prime 12% 12 samples wells Generon Cat# 43266.01
SIGMAFAST BCIP/NBT Sigma-Aldrich Cat#5655
BODIPY FL Vancomycin ThermoFisher Scientific Cat# V34850
Trizol LS Reagent ThermoFisher Scientific Cat#10296010
Recombinant 6xHis-tagged CwlM This study N/A
Recombinant 6XHis-tagged MurJ ICD This study N/A
Recombinant 6xHis-tagged 6xHis-MurJE541-F680 This study N/A
Recombinant GST-tagged FhaA This study N/A
Rv0020c_FHA domain Roumestand et al., 2011 N/A
Recombinant GST-tagged Wag31 This study N/A
Critical Commercial Assays
GenElute Plasmid Miniprep kit Sigma-Aldrich Cat# PLN350
QIAquick Gel Extraction Kit QIAGEN Cat# 28706
QIAquick PCR Purification Kit QIAGEN Cat# 28106
GeneArt Site-Directed Mutagenesis PLUS System ThermoFisher Scientific Cat#A14604
Turbo DNA-free kit ThermoFisher Scientific Cat#AM1907
SuperScript Reverse Transcriptase II ThermoFisher Scientific Cat#18064022
Absolute QPCR SYBR Green mix ThermoFisher Scientific Cat#AB4322B
Platinum Taq DNA polymerase ThermoFisher Scientific Cat# 10966034
Restriction enzymes New England Biolabs(UK) Ltd- / Cat #R3193S; R3182L; R0111L;
R3136L; R3142L
LigaFast Rapid DNA Ligation System Promega Cat# M8221
SignalFire Elite ECL Reagent Cell Signaling Technology Cat#12757S
Titansphere Phos-TiO Kit GL Sciences Cat# 5010-21311
Deposited Data
Raw and analyzed phosphoproteomics data ProteomeXchange
Consortium via the PRIDE
PXD009239 and 10.6019/PXD009239
Oligonucleotides
Oligonucleotides were custom synthesized
(details provided in Table S4)
Sigma Aldrich N/A
Recombinant DNA
Purified Genomic DNA from NR-13648 M. tuberculosis
Strain H37Rv
BEI-Resources NR-48669
Mycobacterial protein fragment complementation (M-PFC) Singh et al., 2006 N/A
Integrating plasmid pMV306 Baek et al., 2011 N/A
pAZI9479 suicide vector. Forti et al., 2009 N/A
pET15bTEV Canova et al., 2008 N/A
GST-tagged PknB-(1-331) Molle et al., 2006 N/A
Software and Algorithms
Xcalibur software ThermoFisher Scientific Version 2.0 SR2 Core,
RRID:SCR_014593
Progenesis LC-MS software Nonlinear Dynamics Hauck
et al., 2010
Version 2.4, Nonlinear
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MASCOT Matrix Science, London, UK Version 2.2.04, RRID:SCR_014322
Scaffold Q+ Proteome Software Inc.,
Portland, OR
Version 4.8.1
Proteome Discoverer Thermo Scientific Version 1.4.1.14, RRID:SCR_014477
X!Tandem The GPM, thegpm.org Version CYCLONE 2010.12.01.1,
RRID:SCR_015645CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to and will be fulfilled by the Lead Contact, Galina V. Mukamolova
(gvm4@leicester.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
M. tuberculosis and M. smegmatis were grown in Middlebrook 7H9 liquid medium supplemented with 10% (v/v) Albumin-Dextrose
Complex (ADC), 0.2% (v/v) glycerol and 0.1% (w/v) at 37Cwith shaking at 100 rpm. Antimicrobials were added at the following con-
centrations (mg/ml): hygromycin 50; kanamycin 50; pristinamycin 0.5; trimethoprim 15. Sucrose magnesium medium (SMM) con-
tained 0.3 M sucrose, 20 mM MgSO4, 0.1% Tween 80 (w/v), 10% (v/v) ADC in standard 7H9 broth. Bacterial growth was followed
by measurement of absorbance at 580 nm, using a spectrophotometer, or by colony-forming unit (CFU) counting on 7H10 agar.
METHODS DETAILS
Generation of M. tuberculosis mutants
To generate cwlM-CM, a 50-prime fragment of the cwlM gene (800 bp) fromM. tuberculosiswas amplified using primers CMRv3915F
and CMRv3915R forM. tuberculosis (Table S5). This fragment was cloned into NcoI and SphI sites of the pAZI9479 plasmid. Trans-
formants were selected on 7H10 agar containing hygromycin and pristinamycin. Single crossovers were confirmed by PCR using
primers FG2224 and FG3106.
For cwlM-CM complementation, a coding sequence of Rv3915 (cwlM) with a 200 bp-upstream region was amplified from the
M. tuberculosis genome using primers Rv3915pMV306F2 and Rv3915pMV306R1. The resulting fragment was cloned into the
KpnI and HindIII sites of the pMV306 plasmid. Transformants were selected on 7H10 medium containing hygromycin, kanamycin
and pristinamycin. CwlM variants were obtained using a GeneArt Site-Directed Mutagenesis System and the primers used are listed
in Table S5. All constructs were sequenced by GATC Biotech before further applications.
Peptidoglycan labeling and microscopy
M. tuberculosis cells were incubated with a mixture of vancomycin and BODIPY FL vancomycin for 24 hours with shaking at 37C.
Mycobacteria were washed with PBS and fixed in 2% (w/v) paraformaldehyde in PBS for 24 hours before imaging using a 12/10bit,
high-speed Peltier-cooled CCD camera (FDI, Photonic Science) using Image-Pro Plus (Media Cybernetics) software.
For scanning electron microscopy (SEM), mycobacteria from exponential phase were washed in PBS before fixation in 2.5%
glutaraldehyde in PBS for 24 hours at room temperature. After further PBS washes, cells were dispensed onto a poly-L-lysine coated
glass slide, before further fixation with 1% aqueous osmium tetroxide at room temperature. Extensively washed glass slides were
mounted onto aluminum stubs, coatedwith gold/palladium in aQuorumQ150 TES coating unit, andwere then imaged using aHitachi
S3000H SEM with an accelerating voltage of 10kV.
Transcriptional Profiling
Total RNA was isolated from 10 mL of mycobacterial cultures using the Trizol reagent, and cDNA samples were generated using
Superscript Reverse Transcriptase II and gene-specific primers. Q-PCR was performed in a Corbett Rotor Gene 6000 real time
thermocycler using Absolute QPCR SYBR Green mix, as described previously (Turapov et al., 2015).
Mycobacterial protein fragment complementation assay
Genes of interest were amplified from theM. tuberculosis genome and were cloned in corresponding plasmids. CwlMwas cloned in
pUAB100 (replacing the GCN4 leucine zipper domain) and in pUAB300 (Singh et al., 2006) to generate fusion proteins with dihydro-
folate reductase domains. Full length dnaA, fhaA, ftsE, ftsZ, cwsA andmurJicdwere cloned in pUAB200 (replacing the GCN4 leucine
zipper domain) and pUAB400 plasmids.M. smegmatis transformants were spotted on 7H10 plates supplemented with hygromycin,
kanamycin and trimethoprim.e3 Cell Reports 25, 57–67.e1–e5, October 2, 2018
Mycobacterial cell fractionation
Mycobacteria were lysed in a Minilys homogenizer (Bertin Instruments) using glass beads in TBS buffer containing 20 mM TrisCl,
pH 8.0, 150 mM NaCl, 20 mM KCl, 10 mM MgCl2, and proteinase/phosphatase inhibitors. Lysates were centrifuged at 27,000 x g
for 1 hour (pellets discarded), followed by 4-hour centrifugation at 100,000 x g. The supernatants contained cytoplasmic proteins
(cytoplasmic fraction); the pellets (membrane fractions) were washed once in carbonate buffer, pH 11 and twice in TBS buffer.
Proteins from cellular fractions were separated on SDS-PAGE. The purity of fractions was confirmed by the detection of diagnostic
proteins, GarA (cytoplasmic protein) and GlnA (membrane protein).
Isolation of recombinant proteins
CwlM,murJicd, murJE541-F680, fhaA, wag31were amplified from theM. tuberculosis genome using corresponding primers (Table S2)
and were cloned either in pET15-TEV (cwlM, murJcd, murJE541-F680) or in pGEX2T (fhaA and wag31). After confirmation by
sequencing, the constructs were transformed into E. coli OverExpress C41(DE3) competent cells. E. coli strains were grown to
OD 0.5 and protein expression was induced with 0.5 mM IPTG followed by incubation at 16C overnight. The recombinant proteins
were purified using affinity chromatography and size exclusion chromatography.
Protein Electrophoresis and Western Blot
Proteins were separated on 4%–20% gradient SERVA gels and transferred onto a nitrocellulose membrane using a Trans-Blot
Turbo Transfer System (Bio-Rad). SIGMAFAST BCIP/NBT or SignalFire Elite ECL Reagent were used to visualize proteins on
C-DiGit Chemiluminescent Blot Scanner (LI-COR Biosciences), according to the manufacturer’s instructions.
Immunoprecipitation assays
Anti-CwlM-IgG Sepharose was prepared by cross-linking the anti-CwlM antibody to cyanogen bromide-activated-Sepharose 4B.
For immunoprecipitation assays, cellular fractions (100 mg proteins in 1mL) were mixed with 10 mL of anti-CwlM-IgG-Sepharose and
incubated for 60min on a laboratory rotator, followed by centrifugation for 5min at 500 x g. Supernatants were removed and the resin
pellets were washed 3 times with TBS. Proteins were extracted with 40 mL of phosphoric acid, pH 2.0, dried and used for western blot
and mass spectrometry analyses. Cellular fractions from the CwlM-depleted mutant served as a control to detect non-specifically
binding or contaminating proteins.
For confirmation of interactions, recombinant CwlM and other proteins (10 mg each) were mixed in phosphate buffer (20 mM
KH2PO4, pH 7.0, 100 mM NaCl, 10 mM KCl) with 10 mL of anti-CwlM-IgG-Sepharose and processed as described above.
In vitro protein phosphorylation by PknB
Purified recombinant CwlM (10 mM) was mixed with the recombinant catalytic domain of PknB (5 mM) in a kinase buffer (20 mM
Tris–HCl, pH 8.0; 0.5 mMDTT; 10 mMMgCl2; 0.1 mM ATP) and incubated at 37
C for one hour. To identify phosphorylated residues,
trypsin-digested proteins were analyzed using a LTQ-Orbitrap-Velos mass spectrometer.
Quantitative label-free phosphoproteomics analysis and phosphopeptide quantification
PknB-CM cultures were centrifuged, washed twice in PBS and resuspended in buffer containing 20mMTrisCl, pH 7.5, 1MNaCl, 8M
urea, and proteinase/phosphatase inhibitors. After bead beating, lysates were cleared by centrifugation and filtration (0.22 mm) and
treated using the FASP protocol, as described previously (Wisniewski et al., 2009). Desalted samples were enriched on TiO2 beads
(Thingholm et al., 2006), speed vacuumed to dryness and re-suspended in 1% formic acid. Trypsin-digested peptides were sepa-
rated using an Ultimate 3000 RSLC (Thermo Scientific) nanoflow LC system and Acclaim PepMap100 nanoViper C18 trap column
(100 mm inner-diameter, 2cm; Thermo Scientific). After trap enrichment, peptides were eluted onto an Acclaim PepMap RSLC nano-
Viper, C18 column (75 mm, 15 cm; ThermoScientific) with a linear gradient of 2%–40% solvent B (80% acetonitrile with 0.08% formic
acid). The HPLC system was coupled to a linear ion trap Orbitrap hybrid mass spectrometer (LTQ-Orbitrap Velos, Thermo Scientific)
via a nanoelectrospray ion source (Thermo Scientific). Data were acquired using the Xcalibur software. The acquired spectra
(Thermo.raw files) were loaded to the Progenesis LC-MS software (version 2.4, Nonlinear) for label free quantification (Hauck
et al., 2010). Three biological replicates for each sample were analyzed. Profile data of the MS scans were transformed to peak lists
with Progenesis LC-MS using a proprietary algorithm. The database search was performed with MASCOT (version 2.3.2, Matrix
Science, London, UK).
NMR chemical shift mapping
FHA 1HN and
15N backbone chemical shift perturbations (Dd) were measured from 1H-15N HSQC experiments upon titration with
different peptides corresponding to the C-terminal phosphorylated part of CwlM (378NDRPTGTFTFAELLA392). 1H-15N HSQC exper-
iments were carried out at 20C on a Bruker Avance III 800 spectrometer, equipped with 5mm z-gradient TCI cryoprobe. 15N-labeled
Rv0020c-FHA domain (80 mM) was dissolved in 10 mM sodium phosphate buffer, pH 6.8, 100 mMNaCl, 1 mM Tris-HCl with 5%D2O
for the lock. Six spectra were recorded by adding 80 mMof six different peptides corresponding to different phosphorylation (p) states
of the C-terminal part of CwlM: pT382-T386, T382-pT386, pT382-pT386, T382-T386, A382-A386 and D382-D386. An additional
reference spectrum was taken on a FHA sample without peptides. All 1H -15N HSQC spectra were recorded using a time domainCell Reports 25, 57–67.e1–e5, October 2, 2018 e4
data size of 64 (t1)3 1024 (t2) complex points, and 16 transients per t1 increment. For analysis, 1HN and
15N chemical shift changes
were combined using the equation: Dd = [(DdH)
2 + (DdN 3 (gN/gH))
2]0.5, where values of Dd > 0.078 ppm have been defined as sign.
QUANTIFICATION AND STATISTICAL ANALYSIS
Analysis of growth (Figures 1, 2, S2) was done using Microsoft Excel for Mac Version 15.40. N correspond to independent biological
replicates.
Quantitative label-free phosphoproteomics analysis and phosphopeptide quantification (Table 1 and Table S1): data were ac-
quired using the Xcalibur software and acquired spectra (Thermo.raw files) were loaded to the Progenesis LC-MS software (version
2.4, Nonlinear) for label free quantification (Hauck et al., 2010). Three biological replicates for each sample were analyzed. Profile data
of the MS scans were transformed to peak lists with Progenesis LC-MS using a proprietary algorithm. The database search was per-
formed with MASCOT (version 2.3.2, Matrix Science, London, UK).
Densitometric analyses of protein bands (Figures 1 and 4) were done using ImageJ version 1.51 software. Blots or gels from three
independent experiments were used. PknB intensity was expressed as percentage of PknB produced in the presence of pristinamy-
cin which corresponds to band 2. Protein abundance bound to anti-CwlM IgG Sepharose was expressed as a percentage of total
amount used for immunoprecipitation assays, which corresponds to lane 5 on each gel.
DATA AND SOFTWARE AVAILABILITY
Genebank: ASM19595v2 was used for annotation of M. tuberculosis proteins (https://www.ncbi.nlm.nih.gov/assembly/GCF_
000195955.2/).
The accession numbers for the mass spectrometry proteomics data reported in this paper are ProteomeXchange Consortium via
PRIDE: PXD009239 and 10.6019/PXD009239 (http://www.proteomexchange.org).e5 Cell Reports 25, 57–67.e1–e5, October 2, 2018
